FTSE MIB
34.339,32 +187,92 (+0,55%) Dow Jones
39.387,76 +331,36 (+0,85%) Nasdaq
16.346,26 +43,46 (+0,27%) Nikkei 225
38.229,11 +155,13 (+0,41%) Petrolio
79,93 +0,67 (+0,85%) Bitcoin EUR
58.697,01 +1.615,62 (+2,83%)
NTLA May 2024 17.500 put
| Chiusura precedente | 0,0200 |
| Aperto | 0,0500 |
| Denaro | 0,0000 |
| Lettera | 0,0000 |
| Prezzo d'esercizio | 17,50 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 0,0200 - 0,0500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireIntellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially
- GlobeNewswire
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research collabo
- GlobeNewswire
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Completed identification of all patients for the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) Plans to initiate a global pivotal Phase 3 study of NTLA-2002 as early as Q3 2024, subject to regulatory feedback On track to submit IND application in September for a global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023, subject to regulatory feedbackPlans to present addi
